NADAC acquisition cost data for SPIRIVA RESPIMAT 2.5 MCG INH. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
| 00597010061 | $119.14 | 2022-01-10 | Rx |
Generic: Tiotropium Bromide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $1.3B | 2,011,325 | 455,627 | $14.40 |
| 2020 | $1.2B | 1,644,087 | 371,913 | $15.26 |
| 2021 | $1.0B | 1,375,217 | 323,646 | $16.29 |
| 2022 | $935.5M | 1,181,232 | 280,582 | $17.07 |
| 2023 | $782.9M | 946,781 | 236,984 | $17.73 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $48.0M | 59,841 | 16,728 |
| Ohio | $43.0M | 51,700 | 13,318 |
| Michigan | $42.3M | 48,457 | 13,603 |
| New York | $40.7M | 49,123 | 12,925 |
| Florida | $37.8M | 45,507 | 12,299 |
| Pennsylvania | $33.6M | 44,486 | 10,594 |
| Texas | $33.4M | 39,126 | 11,044 |
| North Carolina | $31.6M | 39,505 | 9,580 |
| Illinois | $31.4M | 36,411 | 9,624 |
| Washington | $28.7M | 33,980 | 8,465 |
| Wisconsin | $28.0M | 34,134 | 7,872 |
| Tennessee | $25.0M | 30,255 | 7,907 |
| Missouri | $22.8M | 29,084 | 6,836 |
| Virginia | $22.6M | 26,820 | 6,839 |
| Massachusetts | $21.6M | 27,330 | 6,888 |
| Indiana | $20.7M | 22,723 | 6,112 |
| Colorado | $20.1M | 23,125 | 6,209 |
| Minnesota | $17.6M | 21,271 | 5,198 |
| Arizona | $15.4M | 17,399 | 4,994 |
| Georgia | $15.3M | 18,400 | 4,734 |
| Kentucky | $15.0M | 18,172 | 4,657 |
| New Jersey | $13.8M | 16,898 | 4,194 |
| Oregon | $13.7M | 16,512 | 4,299 |
| Connecticut | $13.0M | 15,008 | 3,713 |
| Iowa | $11.4M | 14,338 | 3,194 |
| West Virginia | $11.2M | 12,593 | 3,432 |
| Louisiana | $10.7M | 13,612 | 3,548 |
| South Carolina | $9.6M | 11,525 | 3,120 |
| Maine | $8.5M | 8,315 | 2,286 |
| Alabama | $8.2M | 10,078 | 2,533 |
| Arkansas | $7.8M | 10,473 | 2,421 |
| Oklahoma | $7.3M | 9,190 | 2,500 |
| Maryland | $7.2M | 8,448 | 2,402 |
| Kansas | $5.3M | 6,918 | 1,614 |
| Idaho | $5.2M | 6,653 | 1,620 |
| Nevada | $4.8M | 5,208 | 1,536 |
| New Hampshire | $4.7M | 5,390 | 1,410 |
| New Mexico | $4.4M | 5,479 | 1,474 |
| Montana | $4.4M | 5,253 | 1,355 |
| Nebraska | $4.4M | 6,061 | 1,339 |
| Puerto Rico | $4.3M | 7,449 | 1,424 |
| Mississippi | $4.1M | 5,329 | 1,373 |
| Vermont | $4.1M | 4,320 | 1,132 |
| Delaware | $3.4M | 3,920 | 1,031 |
| Rhode Island | $3.3M | 4,893 | 1,070 |
| Utah | $3.1M | 3,717 | 997 |
| North Dakota | $2.1M | 2,901 | 652 |
| District of Columbia | $1.8M | 2,095 | 643 |
| South Dakota | $1.6M | 2,106 | 440 |
| Hawaii | $1.5M | 1,519 | 490 |
| Wyoming | $1.4M | 1,645 | 411 |
| Alaska | $1.3M | 1,271 | 403 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.